Axsome Therapeutics (FRA:19X) 3-Year EBITDA Growth Rate : -22.50% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Axsome Therapeutics 3-Year EBITDA Growth Rate?

Axsome Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-1.27.

During the past 3 years, the average EBITDA Per Share Growth Rate was -22.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -33.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -34.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Axsome Therapeutics was -4.90% per year. The lowest was -113.50% per year. And the median was -30.20% per year.

Competitive Comparison of Axsome Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Axsome Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Axsome Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's 3-Year EBITDA Growth Rate falls into.

Axsome Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Axsome Therapeutics (FRA:19X) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Axsome Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Axsome Therapeutics (FRA:19X) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (FRA:19X) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

AXSM:USA 19X:Germany

Address

22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007

Website

https://www.axsome.com

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.

Axsome Therapeutics (FRA:19X) Headlines

No Headlines